$REPL

Replimune Group, Inc.

Replimune Group develops oncolytic immunotherapies for cancer patients. Its RPx platform uses an engineered herpes simplex virus 1 designed to selectively replicate in tumors and stimulate local and systemic immune responses. The company’s candidates are administered by direct injection into solid tumors. Its lead candidate, RP1, is being studied alone and with anti-PD-1 therapy, particularly for advanced melanoma and other skin cancers. RP2 is being developed for metastatic uveal melanoma and other tumor types, including liver and biliary tract cancers. RP3 is designed to express additional immune-activating proteins, but Replimune is not currently pursuing its further development. Replimune conducts clinical trials and collaborates with other companies on development, including with Bristol Myers Squibb on nivolumab use in the IGNYTE trial and with Roche on a liver cancer study. It operates an approximately 63,000 square foot manufacturing facility in Framingham, Massachusetts. Replimune is headquartered in Woburn, Massachusetts.

AlphAI earnings readFiscal second quarter 2027 · OCT 28Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate UpdateVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
1
0
—
$522K
SLATTERY JOSEPH P
0%
See all $REPL insider activity →

Replimune Earnings Call Highlights Rapid TUDRIQEV Launch

Replimune (REPL) reported Q2 earnings, highlighting rapid adoption of TUDRIQEV, its first commercial product. Despite no product revenue, management noted strong interest from melanoma centers, broad payer access, and improved net loss. Cash position increased to $307.8M. Management declined to provide revenue guidance due to limited visibility.

REPL sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning REPL (Replimune Group, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent REPL coverage spans earnings, financial news and insider activity.

In the last 30 days, REPL insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($522K). The most active reporter was SLATTERY JOSEPH P with 1 filing.

What's driving REPL

  • Piper Sandler kept its Overweight rating on Replimune Group and raised its price target to $27 from $14, suggesting a 23.3% upside from the Nov 13 close of $21.89.

    tradingview.com · Nov 16, 2026

  • No immediate price catalyst; market likely to remain neutral.

    tipranks.com · Nov 15, 2026

  • The insider sale may signal modest negative sentiment.

    SEC EDGAR · Nov 10, 2026

  • The insider sale suggests potential downside pressure on REPL as a key director reduces his holding.

    SEC EDGAR · Nov 4, 2026

  • Leerink Partners kept Replimune Group at Outperform, raising its price target to $31 from $19, a 63.2% increase. The new target implies a 93.0% upside from the Oct 28 close of $16.06.

    tradingview.com · Oct 29, 2026

AlphAI scores every news story that mentions REPL with an AI model for sentiment and relevance, and aggregates insider trades from Replimune Group, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $REPL

Score

Replimune Earnings Call Highlights Rapid TUDRIQEV Launch

Replimune (REPL) reported Q2 earnings, highlighting rapid adoption of TUDRIQEV, its first commercial product. Despite no product revenue, management noted strong interest from melanoma centers, broad payer access, and improved net loss. Cash position increased to $307.8M. Management declined to provide revenue guidance due to limited visibility.

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.

$REPLMedEarnings

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.

Related tickers